SCHEMBL826101

SCHEMBL826101

CCC(C)(C)Oc1nc(N)nc2ccc(-c3ccc(C(=O)NC(C)(C)C)cc3)nc12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP4K4 O95819 2/20 0.38
JAK2 O60674 1/20 0.37
RIPK1 Q13546 1/20 0.34
LMNA P02545 2/20 0.34
HTT P42858 1/20 0.34
MKNK2 Q9HBH9 5/20 0.34
MKNK1 Q9BUB5 4/20 0.33
KDR P35968 2/20 0.33
PLK4 O00444 1/20 0.33
CHEK1 O14757 1/20 0.33
AURKA O14965 1/20 0.33
DAPK3 O43293 1/20 0.33
CHEK2 O96017 1/20 0.33
CDK1 P06493 1/20 0.33
PIM1 P11309 1/20 0.33
RPS6KB1 P23443 1/20 0.33
FLT4 P35916 1/20 0.33
MAPK9 P45984 1/20 0.33
CSNK1D P48730 1/20 0.33
GSK3A P49840 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL825895 0.90 MKNK2 (0.34) MAP4K4MKNK2MKNK1
SCHEMBL826277 0.90 JAK2 (0.39) MAP4K4JAK2RIPK1LMNAMKNK2
SCHEMBL826435 0.89 MKNK2 (0.43) MAP4K4RIPK1MKNK2MKNK1
SCHEMBL823718 0.88 MAP4K4 (0.41) MAP4K4JAK2RIPK1LMNAHTT
SCHEMBL826099 0.87 MKNK1 (0.40) MKNK2MKNK1MAPTALDH1A1L3MBTL1
SCHEMBL826328 0.87 HDAC4 (0.40) MKNK2MKNK1MAPTALDH1A1L3MBTL1
SCHEMBL825927 0.87 MKNK1 (0.43) MAP4K4MKNK2MKNK1
SCHEMBL825728 0.85 MKNK1 (0.44) MAP4K4LMNAMKNK2MKNK1AURKA
SCHEMBL826265 0.84 MKNK1 (0.44) MAP4K4LMNAMKNK2MKNK1AURKA
SCHEMBL823771 0.84 JAK2 (0.38) MAP4K4JAK2RIPK1LMNAMKNK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090324543-A1 PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC (US) 2009-12-31 US claimed
US-8143394-B2 Pyrido(3,2-d)pyrimidines useful for treating viral infections GILEAD SCIENCES, INC. (US) 2012-03-27 US disclosed
US-20090324543-A1 PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC (US) 2009-12-31 US disclosed
WO-2008077649-A1 PYRIDO(3,2-D)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTONS GILEAD SCIENCES, INC. (US) 2008-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090324543-A1 PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS PNPO, DPYD, PLPBP MAP4K4 2930/4885JAK2 885/4885RIPK1 3764/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.